Patent US4483168A successfully refreshed from Google Patents.
Patent US5078673A successfully refreshed from Google Patents.
US5078673A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Selective removal of radiolabeled antibodies
Assignee: Poniard Pharmaceuticals Inc
•
Filing: 1989-03-27
•
Granted: 1992-01-07
•
Expires: 2009-03-27
Abstract
Abstract Methods of treating and imaging tumor sites using radiolabeled antibodies or fragments of antibodies are disclosed. Ex vivo separation of the radiolabeled antibodies is undertaken to improve image quality and treatment efficacy.
Inventors
- 👤 Paul G. Abrams
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 02:41
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30
Claims Analysis
Total Claims: 36
Claim 1
Independent Claim
102 words
A method of treating tumor tissue sites in a mammal comprising: (a) infusing a therapeutically effective amount of radiolabeled antibody or a fragment thereof into said mammal; (b) withdrawing blood from said mammal; (c) separating cellular elements from said blood to produce a serum fraction and returning said cellular elements to said mammal; (d) reducing the titer of radiolabeled antibody or fragments thereof in said serum fraction of said mammal to produce purified serum; (e) infusing said purified serum into said mammal to replace said serum fraction separated in step (c); and (f) monitoring the response of said mammal to said infusion.
Claim 2
Independent Claim
102 words
A method of treating tumor tissue sites in a mammal comprising: (a) infusing a therapeutically effective amount of radiolabeled antibody or a fragment thereof into said mammal; (b) withdrawing blood from said mammal; (c) separating cellular elements from said blood to produce a serum fraction and returning said cellular elements to said mammal; (d) reducing the titer of radiolabeled antibody or fragments thereof in said serum fraction of said mammal to produce purified serum; (e) infusing said purified serum into said mammal to replace said serum fraction separated in step (c); and (f) monitoring the response of said mammal to said infusion.
Claim 3
Dependent Claim
18 words
A method of claim 1, which further comprises the initial step of infusing unlabelled antibody into said mammal.
Claim 4
Dependent Claim
15 words
A method of claim 1, wherein reducing step (d) is accomplished by an affinity column.
Claim 5
Dependent Claim
33 words
A method of claim 3, wherein an anti-idiotype antibody or fragment thereof to the radiolabeled antibody or fragment thereof is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 6
Dependent Claim
33 words
A method of claim 3, wherein an anti-isotype antibody or fragment thereof to the radiolabeled antibody or fragment thereof is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 7
Dependent Claim
33 words
A method of claim 3, wherein an anti-species antibody or fragment thereof to the radiolabeled antibody or fragment thereof is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 8
Dependent Claim
33 words
A method of claim 3, wherein an anti-subclass antibody or fragment thereof to the radiolabeled antibody or fragment thereof is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 9
Dependent Claim
30 words
A method of claim 3, wherein an antigen directed to the radiolabeled antibody or fragment thereof is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 10
Dependent Claim
27 words
A method of claim 3, wherein an antibody directed against a radionuclide chelate is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 11
Dependent Claim
13 words
A method of claim 1, wherein reducing step (d) is accomplished by dilution.
Claim 12
Independent Claim
110 words
A method of imaging tumor tissue sites in a mammal comprising: (a) infusing an amount of radiolabeled antibody or a fragment thereof sufficient to obtain a diagnostic image; (b) withdrawing blood from said mammal; (c) separating cellular elements from said blood to produce a serum fraction and returning said elements to said mammal; (d) reducing the titer of radiolabeled antibody or fragments thereof in said serum fraction of said mammal to produce purified serum; (e) infusing said purified serum into said mammal to replace said serum fraction separated in step (c); and (f) imaging said tissue site, whereby medical conditions involving tumor tissue sites may be detected, evaluated and monitored.
Claim 13
Independent Claim
110 words
A method of imaging tumor tissue sites in a mammal comprising: (a) infusing an amount of radiolabeled antibody or a fragment thereof sufficient to obtain a diagnostic image; (b) withdrawing blood from said mammal; (c) separating cellular elements from said blood to produce a serum fraction and returning said elements to said mammal; (d) reducing the titer of radiolabeled antibody or fragments thereof in said serum fraction of said mammal to produce purified serum; (e) infusing said purified serum into said mammal to replace said serum fraction separated in step (c); and (f) imaging said tissue site, whereby medical conditions involving tumor tissue sites may be detected, evaluated and monitored.
Claim 14
Dependent Claim
18 words
A method of claim 11, which further comprises the initial step of infusing unlabelled antibody into said mammal.
Claim 15
Dependent Claim
15 words
A method of claim 11, wherein reducing step (d) is accomplished by an affinity column.
Claim 16
Dependent Claim
33 words
A method of claim 13, wherein an anti-idiotype antibody or fragment thereof to the radiolabeled antibody or fragment thereof is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 17
Dependent Claim
33 words
A method of claim 13, wherein an anti-isotype antibody or fragment thereof to the radiolabeled antibody or fragment thereof is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 18
Dependent Claim
33 words
A method of claim 13, wherein an anti-species antibody or fragment thereof to the radiolabeled antibody or fragment thereof is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 19
Dependent Claim
33 words
A method of claim 13, wherein an anti-subclass antibody or fragment thereof to the radiolabeled antibody or fragment thereof is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 20
Dependent Claim
30 words
A method of claim 13, wherein an antigen directed to the radiolabeled antibody or fragment thereof is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 21
Dependent Claim
27 words
A method of claim 13, wherein an antibody directed against a radionuclide chelate is bound to said affinity column to remove said radiolabeled antibody or fragment thereof.
Claim 22
Dependent Claim
13 words
A method of claim 11, wherein reducing step (d) is accomplished by dilution.
Claim 23
Independent Claim
117 words
A method of treating tumor tissue sites in a mammal comprising: (a) biotinylating or avidinylating and radiolabeling an antibody or a fragment thereof; (b) infusing a therapeutically effective amount of biotinylated or avidinylated, radiolabeled antibody or a fragment thereof into said mammal; (c) withdrawing blood from said mammal; (d) separating cellular elements from said blood to produce a serum fraction and returning said cellular elements to said mammal; (e) reducing the titer of radiolabeled antibody or fragments thereof in said serum fraction of said mammal to produce purified serum; (f) infusing said purified serum into said mammal to replace said serum fraction separated in step (d); and (g) monitoring the response of said mammal to said infusion.
Claim 24
Independent Claim
117 words
A method of treating tumor tissue sites in a mammal comprising: (a) biotinylating or avidinylating and radiolabeling an antibody or a fragment thereof; (b) infusing a therapeutically effective amount of biotinylated or avidinylated, radiolabeled antibody or a fragment thereof into said mammal; (c) withdrawing blood from said mammal; (d) separating cellular elements from said blood to produce a serum fraction and returning said cellular elements to said mammal; (e) reducing the titer of radiolabeled antibody or fragments thereof in said serum fraction of said mammal to produce purified serum; (f) infusing said purified serum into said mammal to replace said serum fraction separated in step (d); and (g) monitoring the response of said mammal to said infusion.
Claim 25
Dependent Claim
18 words
A method of claim 21, which further comprises the initial step of infusing unlabeled antibody into said mammal.
Claim 26
Dependent Claim
15 words
A method of claim 21, wherein reducing step (e) is accomplished by an affinity column.
Claim 27
Dependent Claim
22 words
A method of claim 23, wherein avidin is bound to said affinity column to remove said biotinylated, radiolabeled antibody or fragment thereof.
Claim 28
Dependent Claim
22 words
A method of claim 23, wherein biotin is bound to said affinity column to remove said avidinylated, radiolabeled antibody or fragment thereof.
Claim 29
Dependent Claim
13 words
A method of claim 21, wherein reducing step (e) is accomplished by dilution.
Claim 30
Independent Claim
126 words
A method of imaging tumor tissue sites in a mammal comprising: (a) biotinylating or avidinylating and radiolabeling an antibody or a fragment thereof; (b) infusing an amount of biotinylated or avidinylated, radiolabeled antibody or a fragment thereof sufficient to obtain a diagnostic image; (c) withdrawing blood from said mammal; (d) separating cellular elements from said blood to produce a serum fraction and returning said cellular elements to said mammal; (e) reducing the titer of radiolabeled antibody or fragments thereof in said serum fraction of said mammal to produce purified serum; (f) infusing said purified serum into said mammal to replace said serum fraction separated in step; (d); and (g) imaging said tissue site, whereby medical conditions involving tumor tissue sites may be detected, evaluated and monitored.
Claim 31
Independent Claim
126 words
A method of imaging tumor tissue sites in a mammal comprising: (a) biotinylating or avidinylating and radiolabeling an antibody or a fragment thereof; (b) infusing an amount of biotinylated or avidinylated, radiolabeled antibody or a fragment thereof sufficient to obtain a diagnostic image; (c) withdrawing blood from said mammal; (d) separating cellular elements from said blood to produce a serum fraction and returning said cellular elements to said mammal; (e) reducing the titer of radiolabeled antibody or fragments thereof in said serum fraction of said mammal to produce purified serum; (f) infusing said purified serum into said mammal to replace said serum fraction separated in step; (d); and (g) imaging said tissue site, whereby medical conditions involving tumor tissue sites may be detected, evaluated and monitored.
Claim 32
Dependent Claim
18 words
A method of claim 27, which further comprises the initial step of infusing unlabeled antibody into said mammal.
Claim 33
Dependent Claim
15 words
A method of claim 27, wherein reducing step (e) is accomplished by an affinity column.
Claim 34
Dependent Claim
22 words
A method of claim 29, wherein avidin is bound to said affinity column to remove said biotinylated, radiolabeled antibody or fragment thereof.
Claim 35
Dependent Claim
22 words
A method of claim 29, wherein biotin is bound to said affinity column to remove said avidinylated, radiolabeled antibody or fragment thereof.
Claim 36
Dependent Claim
13 words
A method of claim 27, wherein reducing step (e) is accomplished by dilution.
References Cited (Backward Citations)
US4182780A
Cited
USRE31712E
Cited
US4444744A
Cited
US4454106A
Cited
US4563170A
Cited
US4737544A
Cited
US4687808A
Cited
US4605394A
Cited
US4540401A
Cited
US4624846A
Cited
US4681870A
Cited
US4711839A
Cited
EP0272792A1
Cited
EP0273566A1
Cited
US4820261A
Cited
US4896780A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-01-06 | 1995-07-08 | 1996-01-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-01-06 | 1999-07-08 | 2000-01-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-01-06 | 2003-07-08 | 2004-01-07 | $7700.00 | Window Closed / Lapsed |